Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TIPC_TIL_IP

Financiado

Cerrado

T cell based immunotherapy in pancreatic cancer basic concepts and pre clinica...

T cell based immunotherapy in pancreatic cancer basic concepts and pre clinical development Pancreatic ductal adenocarcinoma (PDA) has a devastating prognosis and novel treatment approaches are urgently needed. T cell-based immunotherapy making use of in vitro expanded tumor-infiltrating lymphocytes (TIL) has recently em... ver más

31/08/2017

GERMAN CANCER RESE...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GERMAN CANCER RESEARCH CENTE...

0.00€ | Lider

Proyectos interesantes

PID2021-125981OB-I00

Medical Technol...

Cancer Research

212K€ Cerrado

CNS2023-145343

Medical Technol...

Immunology

200K€ Cerrado

SAF2015-65157-R

Medical Technol...

Data Science

Cerrado

PLEC2022-009428

Medical Technol...

Data Science

808K€ Cerrado

PLEC2021-008094

Medical Technol...

Data Science

104K€ Cerrado

PanCaVax

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Pancreatic ductal adenocarcinoma (PDA) has a devastating prognosis and novel treatment approaches are urgently needed. T cell-based immunotherapy making use of in vitro expanded tumor-infiltrating lymphocytes (TIL) has recently emerged as a potent therapy in melanoma, with the potential to cure even patients with advanced disease. We are currently working towards the development of TIL therapy for PDA on basis of our following findings: • Although PDA has been branded poorly immunogenic, we found most tumors contain a rich immune infiltrate that comprises high numbers of T-cells • Most T-cells display an activated phenotype, while the fraction of CD4+ T-regulatory cells is not higher than that found in peripheral blood of healthy subjects • TILs from PDA biopsies can readily be cultured and expanded, with the same efficiency as melanoma TILs. Given these findings, the malignancy of PDA and the high unmet medical need it represents, we strongly feel that TIL therapy could offer the potent, fast-acting treatment approach we are looking for. Our project has two major aims: • To achieve pre-clinical proof of concept for the anti-tumor action of PDA-derived TILs, as a prelude to clinical application of TIL therapy in this disease. • To obtain in-depth insight in the character and antigen-specificity of the natural TIL response in PDA Our effort is part of a multi-disciplinary program on PDA that is based on the availability of large numbers of tumor biopsies from the European Pancreas Center, one of the world’s largest clinical centers for pancreatic surgery (>400 PDA resections yearly). Within this program, samples from each tumor will be used not only for TIL isolation, but also for establishing xenografts, exome sequencing and histological evaluation of tumor biological/immunological biomarkers. The availability of matched xenografts and exome/histology data will allow us to incisively study the functionality of our TIL cultures.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores